1/10 .,6$h5h1%√∏/*√∏6√∏ 
1. %(√π(5√∏7,%%√∏h5h1h1$', 
APOJECT 50 mg/5 ml enjeksiyonluk √ß√∂zelti i√ßeren ampul 
2. .$/√∏7$7√∏)9(.$17√∏7$7√∏)%√∏/(√π√∏0 
Etkin madde:Her ampul etkin madde olarak 50 mg apomorfin hidroklor√ºr i√ßerir. 
7RSODPo|]HOWLPLNWDU√ï 5 ml‚Äôdir. 
<DUG√ïPF√ïPDGGHOHU Sodyum metabis√ºlfit (E223) 5 mg (her ml‚Äôde 1 mg) 
<DUG√ïPF√ï maddeler i√ßin ¬∂HEDN√ïQ√ï] 
3. FARMAS g7√∏ K FOR M
Enjeksiyonluk √ß√∂zelti 
Berrak ve renksiz √ß√∂zelti 
pH 3.0-5.0
4. ./√∏1√∏.g=(//√∏./(5 
4.1. Terap√∂tik endikasyonlar 
Parkinsonlu hastalarda oral Parkinson tedavisiyle yeterince kontrol edi lemeyen motor 
GDOJDODQPDODU√ïQ ‚Äúon-off‚Äù fenomeni) tedavisinde endikedir. 
4.2.3R]RORMLYHX\JXODPD√∫HNOL 
3R]RORMLX\JXODPDV√ïNO√ï√∑√ïYHV¬ÅUHVL 
APOJECT HQMHNVL\RQXLoLQX\JXQKDVWDODU√ïQVHoLPL 
APOJECT ile tedavi i√ßin se√ßilen hastalar √ïQ ¬≥RII¬¥ VHPSWRPODU√ïQ√ïQ ED√∫ODQJ√ïF√ïQ√ï 
WDQ√ïPOD\DELOL\RU ROPDV√ï JHUHNPHNWHGLU +DVWDODU , kendilerine enjeksiyon yapabilecek yetiye 
VDKLS ROPDO√ïG√ïU YH\D JHUHNWL√∑LQGH NHQGLOHULQH HQMHNVL\RQ \DSDELOHFHN VRUXPOX ELU NL√∫LQLQ 
EXOXQPDV√ïJHUHNPHNWHGLU 
7HGDYL\HED√∫ODPDGDQ|QFHKDVWDQ√ïQ en az iki g√ºn boyunca, genellikle g√ºnde √º√ß defa 20 mg 
domperidon tedavisi al PDV√ïJHUHNOLGLU 
Apomorfin uzman kliniklerdeki NRQWUROO¬Å RUWDPODUGD ED√∫ODQPDO√ïG√ïU Hasta, Parkinson 
KDVWDO√ï√∑√ïQ√ïQ WHGDYLVLQGH uzman bir doktor (√∂rn. n√∂rolog) WDUDI√ïQGDQ L]OHQPHOLGLU APOJECT 
WHGDYLVLQHED√∫ODQPDGDQ|QFHKDVWDQ√ïQOHYRGRSDWHGDY isi, dopamin agonistleriyle birlikte veya 
dopamin agonistleri olmadan optimize edilmelidir.  
<HWL√∫NLQOHU 
8\JXODPD√∫HNOL :
APOJECT PJPOHQMHNVL\RQOXNo|]HOWLLoHUHQDPSXODUDO√ïNO√ïEROXVHQMHNVL\ RQODVXEN¬ÅWDQ 
NXOODQ√ïP LoLQGLU APOJECT ampul, mini- SRPSD YH\D √∫√ïU√ïQJD V¬ÅU¬ÅF¬ÅV¬Å\OH V¬ÅUHNOL VXEN¬ÅWDQ 
inf√ºzyonla da uygulanabilir. 2/10 $SRPRUILQLQWUDYHQ|]\ROODNXOODQ√ïOPDPDO√ïG√ïU 
d|]HOWL \H√∫LOH G|QP¬Å√∫VH NXOODQPD\√ïQ√ï] d|]HOWL NXOODQ√ïP |QFHVLQGH J|UV HO RODUDN 
incelenmelidir. Sadece berrak, renksiz YHSDUWLN¬ÅOLoHUPH\HQo|]HOWLOHUNXOODQ√ïOPDO√ïG√ïU 
(√∫LNGR]XQWD\LQL :
Her hasta i√ßin uygun doz, artan doz p URJUDP√ï\OD EHOLUOHQLU$√∫D√∑√ïGDNLS rogram √∂nerilir: 
<DNOD√∫√ïN RODUDN  - PLNURJUDPNJ
D H√∫GH√∑HU  PJ D pomorfin HCl (0.1 ml) hipokinetik 
veya ‚Äúoff‚Äù SHUL\RGXV√ïUDV√ïQGDVXEN¬ÅWDQRODUDNHQMHNWHHGLO ebilir YHKDVWDPRWRU\DQ√ïWLoLQ 
dakika boyunca g√∂zlenir. 
(√∑HU \DQ√ïW\RNVDYH\D \DQ√ïW\HWHUVL]VHPJDSRPRUILQ+&OLNL QFLGR]XPO subk√ºtan 
olarak enjekte edilir. Hasta daha sonraki 30 dakika boyun FD\HWHUOL\DQ√ïWLoLQJ|]OHQLU 
'R]DM \HWHUOL PRWRU \DQ√ïW VD√∑ODQ√ïQFD\D NDGDU DUG√ïO HQMHNVL\RQODU OD HQ D]  GDNLNDO√ïN 
DUDO√ïNODUODDUW√ïU√ïODELOLU 
7HGDYLQLQNXUXOPDV√ï :
Uygun dozun tayin edilmesiyle tek subk√ºtan enjeksiyon ‚Äúoff‚Äù HSL]RGXQXQLONEHOLUWLOHULQGHG√ï√∫ 
NDOoDYH\DDOWNDU√ïQD \DS√ïODELOLU$EVRUEVL\RQXQWHNELUNL√∫LGHIDU NO√ïHQMHNVL\RQE|OJHOHULQH 
J|UH IDUNO√ï RODELOHFH√∑L XQXWXOPDPDO√ïG√ïU %X sebepten hasta, daha sonraki saatler i√ßinde 
WHGDYL\H \DQ√ïW YHUPH NDOLWHVL Do√ïV√ïQGDQ J|]OHQPHOLGLU +DVWDQ√ïQ \DQ√ïW√ïQD J|UH GR]DMGD 
GH√∑L√∫LNOLNOHU\DS√ïODELOLU 
2SWLPDO DSRPRUILQ KLGURNORU¬ÅU GR]X ELUH\OHU DUDV√ï GH√∑L√∫NHQOLN J|VWHUHEL OLU DQFDN ELU NHUH 
EHOLUOHQGL√∑LQGHKHUKDVWDLoLQJ|UHFHOLRODUDNVDELWNDO√ïU 
7HGDYLQLQV¬ÅUHNOLOL√∑LLoLQ|QO emler:
APOJECT g√ºnl√ºk dozu; 3- PJDUDO√ï√∑√ïLoLQGH √ßR√∑XNH]J¬ÅQGH -10 enjeksiyon √∫HNOLQGHYH 
ED]HQGHD\U√ïHQMHNVL\RQLOHKDVWDODUDUDV√ïGH√∑L√∫NHQOLNJ|VWHULU 
$SRPRUILQ +&O J¬ÅQO¬ÅN WRWDO GR]XQXQ  PJ
√ï D√∫PDPDV√ï |QHULOLU YH ELUH\VHO  EROXV 
HQMHNVL\RQODUPJ
√ïD√∫PDPDO√ïG√ïU 
.OLQLN oDO√ï√∫PDODUGD genellikle levodopa dozunda azal PD VD√∑ODQDELOPL√∫WLU bu etki hastalar 
DUDV√ïGH√∑L√∫NHQOLNJ|VWHULUYHWHFU¬ÅEHOLGRNWRUWDUDI√ïQGDQ dikkatlice d√ºzenlenmesi gereklidir. 
Tedavi belirlendikten sonra, domper LGRQWHGDYLVLED]√ïKDVWDODUGDNDGHPHOLRODUDND]DOW√ïODELOLU 
ancak, √ßok az hastada kusma veya hipotansiyon olmadan ED√∫DU√ï\OD VRQODQG√ïU√ïOP√ï√∫W√ïU 
S√ºrekli inf√ºzyon:
Apomorfin tedavisinin b D√∫ODQJ√ïoEDVDPD√∑√ïQGD iyi bir ‚Äúon‚Äù SHUL\RG\DQ√ïW√ïJ|VWHUHQDQFDNDUD 
HQMHNVL\RQODU NXOODQ√ïOG√ï√∑√ïQGD \HWHUVL] NRQWURO J|VWHUHQ YH\D √ßok ve V√ïN HQMHNVL\RQD LKWL\Do 
duyan (g√ºnde 10'dan fazla) enjeksiyon gerektiren hastalarda D√∫D√∑√ïGDEHOLUWLOGL√∑L√∫HNLOGH mini-
pompa ve/veya √∫√ïU√ïQJD V¬ÅU¬ÅF¬Å s√ºyle s√ºrekli sub N¬ÅWDQ LQI¬Å]\RQ WHGDYLVL ED√∫ODQ abilir veya bu 
WHGDYL\HJHoL√∫\DS√ïODELOLU 
6¬ÅUHNOLLQI¬Å]\RQKHUVDDWWHPJDSRPRUILQ+&OK√ï]√ïQGDPOED√∫OD W√ïO√ïU daha VRQUDNL√∫LVHO 
\DQ√ïWD J|UH DUW√ïU√ïO√ïU √∏QI¬Å]\RQ K√ï]√ïQGDNL DUW√ï√∫ODU  VDDWWHQ  D] ROPD\DQ DUDO√ïNODUGD VDDWWH  
PJ
√ïD√∫PDPDO√ïG√ïU6DDWOLNLQI¬Å]\RQK√ï]ODU√ï -0.06 mg/kg/ saat'e ekivalan 1 mg ile 4 mg 3/10 DUDV√ï nda RODELOLU  P/ YH  P/ √∏QI¬Å zyonlar sadece g√ºnd√ºz saatleri X\JXODQPDO√ïG√ïU 
+DVWD JHFH V¬ÅUHVLQFH √∫LGGHWOL SUREOHPOHU \D√∫DP√ï\RUVD  4 saatlik inf√ºzyonlar √∂nerilmez. 
7HGDYL\H NDU√∫√ï WROHUDQV HQ D] G|UW VDDW ER\XQFD WHGDYLQLQ \DS√ïOPD G√ï√∑√ï bir gece periyodu 
ROPDG√ï√∑√ïV¬ÅUHFHROX√∫PD] .+HUNR√∫XOGDLQI¬Å]\RQE|OJHVLKHUVDDWWHELUGH√∑L√∫WLULOPHOLGLU 
Hastalar JHUHNOL ROGX√∑X WDNGLUGH YH GRNWRUODU√ïQ√ïQ |QHUGL√∑L √∫HNLOGH V¬ÅUHNOL LQI¬Å]\RQ
tedavilerini DUDO√ïNO√ïEROXVHQMHNVL\RQODUOD desteklemeye ihtiya√ß duyabilirler. 
'L√∑HUGRSDPLQDJRQLVWOHULQLQGR]DM√ïQGDD]DOPDV¬ÅUHNOLLQI¬Å]\RQV√ïUDV√ïQGDG¬Å√∫¬ÅQ¬ÅO ebilir.
g]HOSRS¬ÅODV\RQODUDLOL√∫NLQHNELOJLOHU 
B√∂brek/k DUDFL√∑HU\HWPH]OL√∑L :
<HWL√∫NLQOHU YH \D√∫O√ïODU LoLQ |QHULOHQ GR]D EHQ]HU RODQ GR] √∫HPDV√ï E|EUHN \HWPH]OL√∑L RODQ 
hastalar i√ßin takip edilmelidir (bkz. B√∂l√ºm 4.4). 
.DUDFL√∑HU\HWPH]OL√∑LJ|VWHUHQKDVWDODUGDNRQWUHQGLNHGLU 
Pediyatrik pop√ºlasyon:
APOJECT \D√∫√ïQ√ïQDOW√ïQGDNLoRFXN ve adolesanlarda kontrendikedir (bkz. B√∂l√ºm 4.3). 
Geriyatrik pop√ºlasyon:
<D√∫O√ïODU 3 arkinson hasta pop√ºlasyonunu iyi temsil eden gruptur ve apomorfin hidroklor√ºr
NOLQLNoDO√ï√∫PDODU√ïQ√ïQX\JXODQG√ï√∑√ïJUXEXQE¬Å\¬ÅNELUN√ïVP√ïQ√ïROX√∫WXUPDNWDG√ïUO DU APOJECT ile 
WHGDYLJ|UHQ\D√∫O√ïKDVWDODU√ïQWHGDYLVLJHQoKDVWDODUGDQIDUNO√ï GH√∑LOGLU $QFDN\D√∫O√ïKDVWDODUGD 
SRVWXUDO KLSRWDQVL\RQ ULVNL QHGHQL\OH WHGDYLQLQ ED√∫ODQJ√ïF√ïQGD HNVWUD GLNND W HGLOPHVL 
√∂nerilmektedir. 
4.3. Kontrendikasyonlar 
x6ROXQXP GHSUHV\RQX EXQDPD SVLNRWLN KDVWDO√ïN lar YH\D NDUDFL√∑HU \HWPH]OL√∑L olan 
hastalarda kontrendikedir. 
xASRPRUILQ+&OWHGDYLVLOHYRGRSD\D \DQ√ïW√ï RQ RODQ√∫LGGHWOLGLVNLQH]LYH \DGLVWRQL 
g√∂steren hastalar DX\JXODQPDPDO√ïG√ïU 
xAPOJECT, apomorfine veya EXW√ïEEL¬ÅU¬ÅQ¬ÅQELOH√∫HQOHU in GHQKHUKDQJLELULQHNDU√∫√ïD√∫√ïU√ï 
GX\DUO√ïO√ïNJ|VWHUHQNL√∫LOHU eX\JXODQPDPDO√ïG√ïU .
xAPOJECT \D√∫√ïQ√ïQDOW√ïQGDNLoRFXNYHDGROHVDQODUGDNRQWUHQGLNHGLU 
g]HONXOODQ√ïPX\DU√ïODU√ïYH|QOHPOHUL 
Apomorfin +&O EXODQW√ï LOH NXVPD\D H√∑LOLPL RODQ NL√∫LOHUGH YH E|EUHN DNFL√∑HU YH\D 
NDUGL\RYDVN¬ÅOHUKDVWDO√ï√∑√ïRODQNL√∫LOHU e verilirken dikkatli ROXQPDO√ïG√ïU 
<D√∫O√ïODUGDYH /veya G¬Å√∫N¬ÅQKDVWDODUGD WHGDYL\HED√∫ODUNHQHNVWUDGLNNDW edilmelidir.
Apomorfin hipotansiyona QHGHQ ROGX√∑XQGDQ GRPSHULGRQ |Q WHGDYLVL LOH YHULOVH ELOH 
√∂ncesinde NDUGL\DN KDVWDO√ï√∑√ï EXOXQDQ KDVWDODUGD YH\D antihipertansifler gibi vazoaktif ila√ß 
kullanan ve √∂zellikle √∂nceden postural hipotansiyonu olan hastalarda dikkatli NXOODQ√ïOPDO√ïG√ïU 
Apomorfin √∂zellikle y√ºksek dozlarda QT uzama potansiyeli QHVDKLSRODELOHFH√∑LQGHQ torsades 
de pointes aritmi riski EXOXQDQKDVWDODUDX\JXODQ√ïUNHQGLNNDWOLROXQPDO√ïG√ïU 4/10 $SRPRUILQORNDOVXEN¬ÅWDQHWNLOHUOHLOL√∫NLOLGLU%XQODUED]HQHQMHNVL\RQ\ HULQLQURWDV\RQX\OD 
veya nod√ºl DULWH YH HQGXUDV\RQ DODQODU√ï ROX√∫XPXQX HQJHOOHPHN DPDF√ï\OD ultrason 
X\JXODQPDV√ï\OD (uygun ise) D]DOW√ïODELOLU 
Apomorfin ile tedavi edilen KDVWDODUGD KHPROLWLN DQHPL YH WURPERVLWRSHQL ELOGLULOPL√∫WLU 
$SRPRUILQ OHYRGRSD\OD EHUDEHU NXOODQ√ïOG√ï√∑√ïQGD G¬Å]HQOL DUDO√ïNODUGD KHPDWRO RML WHVWOHUL 
X\JXODQPDO√ïG√ïU 
$SRPRUILQ|]HOOLNOHGDUWHUDS|WLNDUDO√ïNO√ïGL√∑HUW√ïEEL¬ÅU¬ÅQOHULOHEL UOLNWHNXOODQ√ïOG√ï√∑√ïQGDGLNNDW 
edilmelidir (bkz. B√∂l√ºm 4.5). 
√∏OHUOHPL√∫ PDUNLQVRQ KDVWDO√ï√∑√ï EXOXQDQ SHN oRN KDVWDGD D\Q√ï ]DPDQGD n√∂ropsikiyatrik 
problemler EXOXQPDNWDG√ïU 1|URSVLNL\DWULN ER]XNOXNODU√ïQ ED]√ï KDVWDODUGD apomorfin 
NXOODQ√ïP√ï\ODN|W¬ÅOH√∫WL√∑LQHLOL√∫NLQNDQ√ïWPHYFXWWXU %XKDVWDODUGD DSRPRUILQNXOODQ√ïUNHQ|]HO 
dikkat gerekmektedir. 
Apomorfin  |]HOOLNOH 3DUNLQVRQ KDVWDODU√ïQGD uyku hali ve aniden gelen uyku HSL]RGODU√ï\OD 
LOL√∫NLOHQGLULOPL√∫WLU . Hastalar bu konuda bilgilendirilmeli ve √∂zellikle ara√ß veya m akine 
NXOODQ√ïUNHQGLNNDWOLROPDODU√ï|QHULOPHOLGLU8\NXKDOL ve/veya ani gelen uyku durumu JHOL√∫HQ 
hastalar ara√ß ve makine kull DQ√ïP√ïQGDQVDN√ïQPDO√ïG√ïU$\U√ïFDGR]DM√ïQD]DOW√ïOPDV√ïG¬Å√∫¬ÅQ¬ÅO ebilir.
'¬ÅUW¬ÅNRQWUROER]XNOXNODU√ï :
+DVWDODUG¬ÅUW¬ÅNRQWUROER]XNOX√∑X JHOL√∫LPLDo√ïV√ïQGDQG¬Å]HQOLRODUDNL]OHQP HOLGLU+DVWDODUYH 
EDN√ïF√ïODU√ï DSRPRUILQ GDKLO GRSDPLQ DQWDJRQLVWOHUL\OH WHGDYL HGLOHQ K DVWDODUGD PH\GDQD 
JHOHELOHFHNSDWRORMLNNXPDUR\QDPDOLELGRDUW√ï√∫√ïKLSHUVHNV¬ÅDOLWHNRPSXO VLIKDUFDPD \DGD 
VDW√ïQ DOPD D√∫√ïU√ï \HPH YH NRPSXOVLI \HPH JLEL G¬ÅUW¬Å NRQWURO ER]XNOX√∑XQXQ GDYUDQ√ï√∫VDO 
VHPSWRPODU√ïQD NDU√∫√ï ELOLQoOL ROPDO√ïG√ïU %X VHPSWRPODU JHOL√∫LUVH  GR]XQ D]DOW√ïOPDV√ïGR]XQ 
D]DOW√ïODUDNNHVLOPHVLG¬Å√∫¬ÅQ¬ÅOPHOLGLU 
APOJECT ampul, nadiren √∫LGGHWOL alerjik reaksiyonlar ve bronkospazma neden olabilen 
sodyum metabis√ºlfit i√ßerir. 
%XW√ïEEL¬ÅU¬ÅQKHUGR]XQGDPPRO¬∂GHQPJGDKDD]VRG\XPLKWLYDHGHU \D QLHVDV√ïQGD 
‚Äúsodyum i√ßermez‚Äù.
4.5.'L√∑HUW√ïEEL¬ÅU¬ÅQOHULOHHWNLOH√∫LPOHUYHGL√∑HUHWNLOH√∫LP√∫HNLO OHUL 
Apomorfin HCl tedavisi i√ßin se√ßilen hastalar √ïQ3DUNLQVRQKDVWDO√ï√∑√ïQ√ïQWHGDYLVLLoLQH√∫]DPDQO√ï 
LODoODUDODFD√∑√ïQHUHGH\VHNHVLQGLU $SRPRUILQ+&OWHGDYLVLQLQED√∫O DQJ√ïF√ïQGDKDVWDROD√∑DQG√ï√∫√ï 
\DQHWNLOHUYHHWNLQLQSRWDQVL\DOL]DV\RQXDo√ïV√ïQGDQJ|]OHQPHOLGLU 
1|UROHSWLNW√ïEEL¬ÅU¬ÅQOHUDSRPRUILQLOHEHUDEHUNXOODQ√ïOG√ï√∑√ïQGD antagonistik etki g√∂sterebilir.
$SRPRUILQ YH NOR]DSLQ DUDV√ï SRWDQVL\HO bir HWNLOH√∫LP EXOXQPDNWDG√ïU I akat klozapin 
Q|URSVLNL\DWULNNRPSOLNDV\RQVHPSWRPODU√ïQ√ïD]DOWPDNLoLQGHNXOODQ√ïODELOLU 
(√∑HU GRSDP in agonistleriyle tedavi g√∂ren P DUNLQVRQ KDVWDODU√ïQGD Q|UROHSWLN W√ïEEL ¬ÅU¬ÅQ ler 
NXOODQ√ïODFDNVD PLQL -SRPSD YH\D √∫√ïU√ïQJD V¬ÅU¬ÅF¬ÅV¬Å\OH YHULOGL√∑L GXUXPGD apomorfin dozunda 
GHUHFHOLD]DOWPDG¬Å√∫¬ÅQ¬ÅO ebilir (Dopaminerjik tedavinin ani kesilmesiyle birlikte, nadir ol arak 
n|UROHSWLNPDOLJQVHQGURPXQXG¬Å√∫¬ÅQG¬ÅUHQVHPSWRPODU ELOGLULOPL√∫WLU 5/10 Antiaritmikler (kinidin, amiodaron vb.), trisiklik antidepresanlar (amitriptilin, imipramin vb.) 
ve makrolit antibiyotikler (eritromisin, azitromisin, klaritromis in vb.) gibi kalp ritmini 
HWNLOHGL√∑LELOLQHQLODoODULOHNXOODQ√ïP√ïQGDGLNNDWOLROXQPDO√ïG√ïU 
$SRPRUILQLQ GL√∑HU W√ïEEL ¬ÅU¬ÅQOHULQ SOD]PD NRQVDQWU aV\RQODU√ï ¬Å]HULQGHNL RODV√ï HWNLOHUL 
oDO√ï√∫√ïOPDP√ï√∫W√ïU %X QHGHQOH DSRPRUILQLQ |]HOOLNOH WHUDS|WLN DUDO√ï √∑√ï GDU RODQ GL√∑HU W√ïEEL 
√ºr√ºnlerle ELUOLNWHNXOODQ√ïP√ïQGDGLNNDWOLROXQPDV√ïWDYVL\HHGLOLU 
$QWLKLSHUWDQVLIYH.DUGL\DN$NWLI7√ïEELhU¬ÅQOHU 
'RPSHULGRQ LOH ELUOLNWH NXOODQ√ïOG√ï√∑√ïQGD GDKL DSRPRUILQ EX W√ïEEL ¬ÅU¬ÅQOHULQ DQWLKL SHUWDQVLI 
HWNLOHULQLDUWW√ïUDELOLUEN]%|O¬ÅP 
47 DUDO√ï√∑√ïQ√ï X]DWW√ï√∑√ï ELOLQHQ GL√∑HU LODoODU LOH DSRPRUILQ X\JXO D nPDV√ïQGDQ NDo√ïQ√ïOPDV√ï 
√∂nerilmektedir. 
g]HOSRS¬ÅODV\RQODUDLOL√∫NLQHNELOJLOHU 
Pediyatrik pop√ºlasyon 
3HGL\DWULNSRS¬ÅODV\RQGDHWNLOH√∫PHoDO√ï√∫PDODU√ï\DS√ïOPDP√ï√∫W√ïU 
4.6. Gebelik ve laktasyon 
Genel tavsiye 
Gebelik kategorisi C‚Äôdir. 
dRFXNGR√∑XUPDSRWDQVL\HOLEXOXQDQNDG√ïQODU'R√∑XPNRQWURO¬Å.RQWUDVHSVL\RQ
APOJECT‚Äôin oRFXNGR√∑XUPDSRWDQVL\HOLEXOXQDQNDG√ïQODUGDNXOODQ√ïP√ïQDLOL√∫NLQ\HWHUOLYHU L 
PHYFXWGH√∑LOGLU 'R√∑XUJDQO√ïNSRWDQVL\HOLRODQNDG√ïQODUGDX\JXQELU kontrasepsiyon y√∂ntemi 
√∂nerilmelidir. 
Gebelik d√∂nemi 
APOJECT'i QJHEHNDG√ïQODUGDNXOODQ√ïP√ïQDLOL√∫NLQ\HWHUOLYHULPHYFXWGH√∑LOGLU 
Hayvanlar √ºzerinde \DS√ïODQ DUD√∫W√ïUPDODU ¬ÅUHPH WRNVLVLWHVLQLQ EXOXQGX√∑XQX J|VWHUPL√∫WLU
√∏QVDQODUD\|QHOLNSRWDQVL\HOULVN bilinmemektedir (bkz. B√∂l√ºm 5.3). 
APOJECT Do√ïNoDJHUHNOLROPDG√ïNoDJHEHOLNG|QHPLQGHNXOODQ√ïOPDPDO√ïG√ïU 
Laktasyon d√∂nemi 
$SRPRUILQLQ LQVDQ V¬ÅW¬Å\OH DW√ïO√ïS DW√ïOPDG√ï√∑√ï ELOLQPHPHNWHGLU $SRPRUILQL Q V¬ÅW LOH DW√ïO√ïP√ï 
KD\YDQODU ¬Å]HULQGH DUD√∫W√ïU√ïOPDP√ï√∫W√ïU Emzirmenin V¬ÅUG¬ÅU¬ÅO¬ÅS V¬ÅUG¬ÅU¬ÅOPH\HFH√∑LQH ya da 
APOJECT tedavisinin V¬ÅUG¬ÅU¬ÅO¬ÅS V¬ÅUG¬ÅU¬ÅOPH\HFH√∑LQH LOL√∫NLQ NDUDU YHULOLUNHQ HP]LUPHQLQ 
oRFXN Do√ïV√ïQGDQ ID\GDV√ï YH APOJECT WHGDYLVLQLQ HP]LUHQ DQQH Do√ïV√ïQGDQ ID\GDV√ï GLNNDWH 
DO√ïQPDO√ïG√ïU 
√úreme \HWHQH√∑L)HUWLOLWH 
+D\YDQ ¬ÅUHPH oDO√ï√∫PDODU√ï herhangi bir teratojenik HWNL\H L√∫DUHW HWPHPHNWH ancak, anneye 
WRNVLNRODQGR]ODUV√ïoDQODUDYHULOGL√∑LQGH\HQLGR√∑DQGDVROXQXP\HWHUVL] OL√∑LQHQHGHQROPX√∫WXU 
√∏QVDQODULoLQSRWDQVL\HOULVNELOLQPHPHNWHGLU (bkz. B√∂l√ºm 5.3).6/10 4.7. Ara√ß ve makine kullan √ïm√ï√ºzerindeki etkiler
Apomorfin HCI‚Äônin ara√ß ve makine NXOODQ√ïP\HWHQH√∑L¬Å]HULQGHKDILIYH\DRUWDGHUHFHGHHWNLVL 
EXOXQPDNWDG√ïU 
Apomorfinle tedavi edilen ve uyku hali ve/veya ani uyku HSL]RGODU√ï g√∂steren hastalar, 
tekrarlayan epizodlar ve uyku hali ortadan kalkana dek, ara√ß kullanma veya dikkat 
ER]XNOX√∑XQXQ NHQGLOHULQL YH GL√∑HU NL√∫LOHUL FLGGL \DUDODQPD YH\D |O¬ÅP ULVNL  DOW√ï na
sokabilecekleri faaliyetlerde bulunmaktan (√∂rn. m DNLQH NXOODQPD VDN√ïQPD konusunda 
bilgilendirilmelidir (bkz. B√∂l√ºm 4.4). 
%X LODo ]LKLQVHO IRQNVL\RQD ]DUDU YHUHELOLU YH KDV WDQ√ïQ J¬ÅYHQOL √∫HNLOGH DUDo NXOODQPD 
\HWHQH√∑LQLHWNLOH\HELOLU%XLODoUHoHWHHGLOLUNHQ KDVWDD√∫D√∑√ïGDNL√∫HNLOGHELOJLOHQGLULOPHOLGLU 
-%XLODF√ïQDUDoNXOODQPD\HWHQH√∑LQL]LHWNLOHPHLKWL PDOLYDUG√ïU 
-√∏ODF√ïQVL]LQDV√ïOHWNLOHGL√∑LQLELOHQHGHNDUDoNXOO DQPD\√ïQ√ï] 
4.8. √∏VWHQPH\HQHWNLOHU 
dRN\D\J√ïQ¬ï 
<D\J√ïQ¬ïLOD 
<D\J√ïQROPD\DQ¬ïLOD 
6H\UHN¬ïLOD 
√áok seyrek (< 1/10.000) 
Bilinmiyor (eldeki verilerden hareketle tahmin edilemiyor). 
Kan ve lenfatik sistem LKDVWDO√ïNODU√ï 
<D\J√ïQ ROPD\DQ Apomorfinle tedavi g√∂ren hastalarda hemolitik anemi ve trombositope ni 
ELOGLULOPL√∫WLU 
Seyrek: $SRPRUILQ+&OLOHWHGDYLV√ïUDV√ïQGDHR]LQRILOLROX√∫PX√∫WXU .
%D√∑√ï√∫√ïNO√ïN sistemi KDVWDO√ïNODU√ï 
Seyrek: 6RG\XP PHWDELV¬ÅOILW YDUO√ï√∑√ïQGDQ GROD\√ï DQDILODNVL YH EURQNRVSD]P GDKL O DOHUMLN 
UHDNVL\RQODUROX√∫DELOLU 
Psikiyatrik KDVWDO√ïNODU :
<D\J√ïQ 3DUNLQVRQ KDVWDODU√ïQGD Q|URSVLNL\DWULN ER]XNOXNODU \D\J√ïQG√ïU APOJECT bu 
KDVWDODUGD GLNNDWOL NXOODQ√ïOPDO√ïG√ïU $SRPRUILQ +&O WHGDYLVL V√ïUDV√ïQGD  JHoLFL KDILI ELOLQo 
EXODQ√ïNO√ï√∑√ïYHJ|UVHOKDO¬ÅVLQDV\RQODUGDKLOQ|URSVLNL\DWULNER]XNOXNODUROX√∫PX√∫WXU .
Bilinmiyor: 
'¬ÅUW¬Å NRQWURO ER]XNOXNODU√ï $ pomorfin dahil olmak √ºzere, dopamin agonistleri ile tedavi 
J|UHQ KDVWDODUGD SDWRORMLN NXPDU R\QDPD FLQVHO LVWHNWH DUW√ï√∫ YH KLSHUVHNV¬ÅDOLWH , kompulsif 
KDUFDPDYH\DVDW√ïQDOPDD√∫√ïU√ï\HPHYHNRPSXOVLI\HPHPH\GDQD gelebilir (bkz. B√∂l√ºm 4.4).
Sinir sistemi KDVWDO√ïNODU√ï :
<D\J√ïQ7HGDYLQLQED√∫ODQJ√ïF√ïQGDDSRPRUILQ+&O ‚ÄôLQKHUGR]X\ODJHoLFLVHGDV\RQROX√∫DELOLUEX 
genellikle ilk birka√ß hafta i√ßinde d√ºzelir. 
Apomorfin uyku KDOLLOHLOL√∫NLOHQGLULOLU 
%D√∫G|QPHVLED\√ïOPDKLVVLELOGLULOPL√∫WLU 7/10 <D\J√ïQ ROPD\DQ Apomorfin ‚Äúon‚Äù SHUL\RGX V√ïUDV√ïQGD ED]√ï GXUXPODUGD √∫LGGHWOL RODELOHQ 
diskineziyi ind√ºkleyebilir ve bu durum birka√ß hastada tedavinin kesilmesi ile sonu√ß lanabilir.
Apomorfin ani uyku HSL]RGODU√ï LOHLOL√∫NLOHQGLULOPL√∫WLU EN]D\U√ïFD%|O¬ÅP .
Vask√ºler KDVWDO√ïNODU :
<D\J√ïQ ROPD\DQ Seyrek olarak postural hipotansiyon g√∂zlenir ve genellikle ge√ßici dir (bkz. 
B√∂l√ºm 4.4).
Solunum, J|√∑¬ÅVKDVWDO√ïNODU√ïYHPHGLDVWLQDOKDVWDO√ïNODU :
<D\J√ïQ$SRPRUILQWHGDYLVLV√ïUDV√ïQGDHVQHPHELOGLULOPL√∫WLU 
<D\J√ïQROPD\DQ6ROXQXPJ¬ÅoO¬ÅNOHULELOGLULOPL√∫WLU 
Gastrointestinal KDVWDO√ïNODU :
<D\J√ïQ Genellikle domperidon kesilmesinin sonucu olarak, √∂zellikle apomorfin teda visine 
LONED√∫ODQG√ï√∑√ïQGDEXODQW√ïYHNXVPDELOGLULOPL√∫WLU (bkz. B√∂l√ºm 4.2). 
Deri ve subk√ºtan doku KDVWDO√ïNODU√ï 
<D\J√ïQROPD\DQ/RNDOYH\D\J√ïQG|N¬ÅQW¬ÅELOGLULOPL√∫WLU 
*HQHOKDVWDO√ïNODUYHX\JXODPDE|OJHVLQHLOL√∫NLQER]XNOXNODU :
dRN \D\J√ïQ dR√∑X KDVWDGD |]HOOLNOH V¬ÅUHNOL NXOODQ√ïPOD HQMHNVL\RQ E|OJH VL UHDNVL\RQODU√ï 
meydana gelmektedir %XQODUDUDV√ïQGDVXEN¬ÅWDQQRG¬ÅOOHUVHUWOH√∫PHHULWHPD√∫√ïU√ï hassasiyet 
ve panik√ºlit yer alabilir. dH√∫LWOL GL√∑HU ORNDO UHDNVL\RQODU da JHOL√∫HELOLU L rritasyon, ND√∫√ïQW√ï 
o¬ÅU¬ÅNOHUYHD√∑U√ïJLEL 
<D\J√ïQRO mayan: (QMHNVL\RQE|OJHVLQHNUR]XYH¬ÅOVHUELOGLULOPL√∫WLU 
Bilinmiyor: 3HULIHUDO|GHPELOGLULOPL√∫WLU 
$UD√∫W√ïUPDODU 
<D\J√ïQGH√∑LO : Apomorfin alan KDVWDODUGDSR]LWLI&RRPEV¬∂WHVWOHULELOGLULOPL√∫WLU 
√π¬ÅSKHOLDGYHUVUHDNVL\RQODU√ïQUDSRUODQPDV√ï 
5XKVDWODQG√ïUPD VRQUDV√ï √∫¬ÅSKHOL LODo DGYHUV UHDNVL\RQODU√ïQ√ïQ UDSRUODQP DV√ï E¬Å\¬ÅN |QHP 
WD√∫√ïPDNWDG√ïU 5DSRUODPD \DS√ïOPDV√ï LODF√ïQ \DUDUULVN GHQJHVLQL Q V¬ÅUHNOL RODUDN L]OHQPHVLQH 
RODQDNVD√∑ODU6D√∑O√ïNPHVOH√∑LPHQVXSODU√ïQ√ïQKHUKDQJLELU√∫¬ÅSKHOLD GYHUVUHDNVL\RQ u T√ºrkiye 
Farmakovijilans Merkezi (T√úFAM)'ne bildirmeleri gerekmektedir  (www.titck.gov.tr; eposta: 
tufam@titck.gov.tr; tel: 0 800 314 00 08; faks: 0 312 218 35 99). 
4.9.'R]D√∫√ïP√ïYHWHGDYLVL 
%X X\JXODPD \ROX\OD DSRPRUILQ D√∫√ïU√ï GR]DM√ï ¬Å]HULQH V√ïQ√ïUO√ï VD\√ï da GHQH\LP EXOXQPDNWDG√ïU 
$√∫√ïU√ïGR]DMVHPSWRPODU√ïD√∫D√∑√ïGD|QHULOGL√∑L√∫HNLOGHHPSLULNRODUDNWHGDYLHG LO ebilir:
x$√∫√ïU√ïNXVPD : Domperidon ile tedavi edilebilir. 
xSolunum depresyonu: Nalokson ile tedavi edilebilir. 
xHipotansiyon  8\JXQ D\DUODPDODU \DS√ïOPDO√ïG√ïU |UQH√∑LQ \DWD√∑√ïQ D\DN \¬ÅNVHNOL √∑LQL 
DUW√ïUPDN 
xBradikardi: Atropinle tedavi edilebilir. 8/10 5. )$50$.2/2-√∏.g=(//√∏./(5 
5.1. Farmakodinamik √∂zellikler 
Farmakoterap√∂tik grup : Dopamin agonistleri 
ATC Kodu : N04BC07 
$SRPRUILQ GRSDPLQ UHVHSW|UOHULQLQ GLUHNW VWLP¬ÅODQ√ïG√ïU YH KHP ' KHP GH '  UHVHSW|U 
DJRQLVWL|]HOOLNOHULJ|VWHULUNHQOHYRGRSDLOHPHWDEROLNYH\DWUDQVSRUW\RODNO DU√ïQ√ïSD\OD√∫PD] 
+HUQHNDGDUGHQH\KD\YDQODU√ïQGD DSRPRUILQX\JXODPDV√ïQLJUR -striatal h√ºcreler LQDWH√∫OHPH 
GH√∫DUM K√ï]√ïQ√ï EDVN√ïODUVD GD G¬Å√∫¬ÅN GR]XQ HQGRMHQ GRSDPLQ VDO√ïQ√ïP√ïQ√ïQ SUH -sinaptik 
LQKLELV\RQX\ODORNRPRWRUDNWLYLWHGHD]DOPD\DQHGHQROGX√∑XJ|VWHULOPL√∫W LU3DUNLQVRQ ‚ÄôDED√∑O√ï 
motor yetersizlik √ºzerine etkisi post-sinaptik resept√∂r b√∂lgel eri ar DF√ïO√ï√∑√ï\ODG√ïU%XELID]LNHWNL 
LQVDQODUGDGDJ|]OHQPL√∫WLU 
5.2. Farmakokinetik √∂zellikler 
Genel √∂zellikler 
$SRPRUILQ VXEN¬ÅWDQ HQMHNVL\RQX VRQUDV√ï IDUPDNRNLQHWL√∑L LNL NRPSDUW√ïPDQO√ï PRGH O ile 
WDQ√ïPODQDELOLU .
Emilim: 
Apomorfin, klinik e WNLOHULQK√ï]O√ïED√∫ODQJ√ïF√ïLOHNR rele (uyumlu) olarak (4-12 dakika) subk√ºtan 
GRNXGDQK√ï]O√ïYHWDPRODUDNDEVRUEHROXU 
'D√∑√ïO√ïP 
6HUHEURVSLQDO V√ïY√ïGDNL DSRPRUILQ VHYL\HVL LOH NOLQLN FHYDS GR√∑UXGDQ LOL√∫NL OLGLU LODF√ïQ 
GD√∑√ïO√ïP√ïQ√ïHQL\LLNLNRPSDUW√ïPDQO√ïPRGHOWDQ√ïPODU 
'D√∑√ïO√ïP\DU√ï|PU¬Å¬ìGDNLNDG√ïU 
Biyotransformasyon: 
$SRPRUILQPHWDEROL]PDV√ïQ√ïQWRSODP√ïQ \DNOD√∫√ïNRODUDN\¬Å]GHRQX√∫HNOLQGHJ OXNXURQLGDV\RQ 
YHV¬ÅOIRQDV\RQDUDF√ïO√ï√∑√ï\ODG√ïUGL√∑HU\RODNODUWDQ√ïPODQPDP√ï√∫W√ïU 
Eliminasyon: 
$QDHOLPLQDV\RQ\ROXE|EUHNDUDF√ïO√ï√∑√ï\ODG√ïU0HWDEROLWOHULDNWLIGH√∑LOGLU  
(OLPLQDV\RQ\DU√ï -|PU¬Å¬ìGDNLNDG√ïU(WNLQPDGGHQLQNOLQLNHWNLVLQLQN√ïVDO√ï√∑√ï \DNOD√∫√ïN 
1 saat) PDGGHQLQK√ï]O√ïNOHUHQVLLOHDo√ïNODQPDNWDG√ïU 
5.3. Klinik √∂ncesi g√ºvenlilik verileri 
.√ïVD¬ÅU¬ÅQELOJLOHULQLQGL√∑HUN√ïV√ïPODU√ïQGD\HUDODQELOJLOHU\DQ√ï QGD , tekrarlanan doz subk√ºtan 
WRNVLVLWHoDO√ï√∫PDODU√ïLQVDQODULoLQ|]HOELUWHKOLNH g√∂stermemektedir. 
√∏Q YLWUR JHQRWRWRNVLVLWH oDO√ï√∫PDODU√ï E¬Å\¬ÅN RODV√ïO√ïNOD DSRPRUILQLQ RNVLGDV\RQX\OD ROX√∫DQ 
¬ÅU¬ÅQOHUGHQ GROD\√ï PXWDMHQLN YH NODVWRMHQLN HWNLOHU J|VWHUPL√∫WLU )DNDW  \DS√ïODQ in vivo 
oDO√ï√∫PDODUGD apomorfin JHQRWRNVLNGH√∑LOGLU 
Apomorfinin √ºreme √ºzerine etkileri V√ïoDQODUGD LQFHOHQPL√∫WLU Apomorfin bu t√ºrlerde 
WHUDWRMHQLN GH√∑LOGLU IDNDW DQQH\H WRNVLN RODQ GR]ODU√ïQ \HQL GR√∑DQGD V ROXQXP J¬ÅoO¬Å√∑¬Å YH 
maternal EDN√ïPGDND\√ïSODUDQHGHQRODELOHFH√∑LND\GHGLOPL√∫WLU 
Herhangi bir k DUVLQRMHQLWHoDO√ï√∫PDV√ï \DS√ïOPDP√ï√∫W√ïU 9/10 6. )$50$6g7√∏.g=(//√∏./(5 
6.1.<DUG√ïPF√ïPDGGHOHULQOLVWHVL 
Sodyum metabis√ºlfit (E223) 
Hidroklorik asit (pH ayarlama V√ï i√ßin) 
Sodyum hidroksit (pH ayarlama V√ï i√ßin) 
Enjeksiyonluk su 
6.2. Ge√ßimsizlikler 
*HoLPVL]OLNoDO√ï√∫PDODU√ïEXOXQPDG√ï√∑√ïQGDQEX¬ÅU¬ÅQGL√∑HUW√ïEEL¬ÅU¬ÅQOHUOHNDU√ï√∫W√ïU√ï OPDPDO√ïG√ïU 
6.3. Raf √∂mr√º 
24 ay
6.4. Saklamaya y√∂nelik √∂zel tedbirler 
25¬∞C‚Äô \LD√∫PD\DQRGDV√ïFDNO√ï√∑√ïQGDVDNOD\√ïQ√ï] 
,√∫√ïNWDQNRUXPDNDPDF√ï\ODRULMLQDOG√ï√∫DPEDODM√ï LoLQGHVDNOD\√ïQ√ï] 
d|]HOWL\L NXOODQ√ïP |QFHVL J|UVHO RODUDN muayene ediniz. Sadece berrak ve renksiz √ß√∂zelti 
LoHUHQDPSXOOHULNXOODQ√ïQ√ï] $PSXOLoLQGHNLo|]HOWL\H√∫LOHG|QP¬Å√∫VHNXOODQPD \√ïQ√ï] 
7HNNXOODQ√ïPO√ïNW√ïU.XOODQ√ïOPD\DQYH\DDUWDNDODQo|]HOWLDW√ïOPDO√ïG√ïU
dRFXNODU√ïQHUL√∫HPH\HFH√∑LYHJ|UHPH\HFH√∑L\HUOHUGHDPEDODM√ïLoLQGHVD NOD\√ïQ√ï] 
6.5.$PEDODM√ïQQLWHOL√∑LYHLoHUL√∑L 
2 ml enjeksiyonluk √ß√∂zelti i√ßeren, Tip 1 cam ampuller, 5 adet ampul i√ßeren kutularda 
mevcuttur. Ampuller, karton kutuda bulunan plastik bir kap i√ßerisindedir. 
6.6.%H√∫HULW√ïEEL¬ÅU¬ÅQOHUGHQDUWDNDODQPDGGHOHULQLPKDV√ïYHGL√∑HU|]HO\|QW HPOHU 
.XOODQ√ïOPDP√ï√∫ RODQ ¬ÅU¬ÅQOHU YH\D DW√ïN PDWHU\DOOHU ¬≥7√ïEEL DW√ïNOD U√ïQ NRQWURO¬Å \|QHWPHOL√∑L¬¥ YH 
¬≥$PEDODMYHDPEDODMDW√ïNODU√ïQ√ïQNRQWURO¬Å\|QHWPHOL√∑L¬¥QHX\JXQRODUDNLPKDHGLO PHOLGLU 
S√ºrekli inf√ºzyon ve mini- SRPSDYH\D√∫√ïU√ïQJDV¬ÅU¬ÅF¬ÅV¬ÅQ¬ÅQNXOODQ√ïP√ï 
Hangi mini- SRPSDYHYH\D√∫√ïU√ïQJDV¬ÅU¬ÅF¬ÅV¬ÅQ¬ÅQNXOODQ√ïODFD√∑√ï ve JHUHNHQGR]DMD\DUODPDODU√ï 
KDVWDQ√ïQNL√∫LVHOLKWL\DF√ïQDJ|UHGRNWRUWDUDI√ïQGDQEHOLUOHQ ecektir.
7. 58+6$76$+√∏%√∏ 
(UD3KDUPD$QDOLWLNd|]¬ÅPOHUYH√∏ODo6DQD\L7LFDUHW$√π 
√πHULIDOL0DK%D\UDNWDU%XOYDU√ï%XUKDQ6RN1R 
hPUDQL\H√∏VWDQEXO 
Tel :0 216 420 35 90 
Faks :0 216 420 35 94 
e-mail :info@erapharma.com.tr 
8. RUHSAT NUMARASI(LARI) 
2016/554
9. √∏/.58+6$77$5√∏+√∏58+6$7<(1√∏/(0(7$5√∏+√∏ 
√∏ONUXKVDWWDULKL 03.08.2016
Ruhsat yenileme tarihi: 10 /10 10..h%¬∂h1<(1√∏/(10(7$5√∏+√∏ 
-